Abstract

The aim of this study was to investigate the prognostic impact of baseline tumor burden and loci on the efficacy of first line renal cancer treatment with sunitinib. Baseline and on-treatment CT scans were evaluated. Both the Kaplan-Meier and Weibull modelling survival estimators have been used to describe sunitinib treatment response. Logistic regression was used to confirm associations between tumor site, burden and survival. Additionally, analysis of the metastases co-occurrence was conducted using the Bayesian inference on treated and external validation cohorts. 100 patients with metastatic clear cell renal cell carcinoma were treated with sunitinib in this study. Presence of metastases in the abdominal region (HR = 3.93), and the number of brain metastases correlate with shorter PFS, while the presence of thoracic metastases (HR = 0.47) with longer PFS. Localization of metastases in the abdominal region significantly impacts risk of metastases development in other locations including bone and brain metastases. Biology of metastases, in particular their localization, requires further molecular and clinical investigation.

Details

Title
Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma
Author
Czarnecka, Anna M 1   VIAFID ORCID Logo  ; Brodziak, Anna 2   VIAFID ORCID Logo  ; Sobczuk Pawel 2   VIAFID ORCID Logo  ; Dendek Cezary 3 ; Labochka Dominika 4 ; Korniluk Jan 1 ; Bartnik Ewa 5 ; Szczylik Cezary 6 

1  Military Institute of Medicine, Department of Oncology, Warsaw, Poland (GRID:grid.415641.3) (ISNI:0000 0004 0620 0839) 
2  Military Institute of Medicine, Department of Oncology, Warsaw, Poland (GRID:grid.415641.3) (ISNI:0000 0004 0620 0839); Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland (GRID:grid.418165.f) (ISNI:0000 0004 0540 2543); Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Department of Experimental and Clinical Physiology, Warsaw, Poland (GRID:grid.13339.3b) (ISNI:0000000113287408) 
3  Warsaw University of Technology, Faculty of Mathematics and Information Science, Warsaw, Poland (GRID:grid.1035.7) (ISNI:0000000099214842); Polish Academy of Sciences, Institute of Computer Science, Warsaw, Poland (GRID:grid.413454.3) (ISNI:0000 0001 1958 0162) 
4  Military Institute of Medicine, Department of Oncology, Warsaw, Poland (GRID:grid.415641.3) (ISNI:0000 0004 0620 0839); Medical University of Warsaw, Department of Pediatrics and Endocrinology, Warsaw, Poland (GRID:grid.13339.3b) (ISNI:0000000113287408) 
5  University of Warsaw, Institute of Genetics and Biotechnology, Faculty of Biology, Warsaw, Poland (GRID:grid.12847.38) (ISNI:0000 0004 1937 1290); Polish Academy of Sciences, Institute of Biochemistry and Biophysics, Warsaw, Poland (GRID:grid.413454.3) (ISNI:0000 0001 1958 0162) 
6  Military Institute of Medicine, Department of Oncology, Warsaw, Poland (GRID:grid.415641.3) (ISNI:0000 0004 0620 0839); Medical Center for Postgraduate Education, Warsaw, Poland (GRID:grid.414852.e) (ISNI:0000 0001 2205 7719); European Health Centre, Department of Oncology, Otwock, Poland (GRID:grid.414852.e) 
Publication year
2019
Publication date
2019
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41598-019-44226-y
ProQuest document ID
2229262996
Copyright
© The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.